The prize recognizes foundational discoveries about regulatory T cells and the FOXP3 gene that redefined immune tolerance and opened avenues to treat autoimmune disease, enable transplantation, and advance immuno-oncology. ISB celebrates Dr. Brunkow’s leadership and collaborative science.
The pioneering work of Mary Brunkow and Fred Ramsdell began with a mysterious mutant mouse known as “scurfy,” leading them to identify the FOXP3 gene and unlock how regulatory T cells prevent autoimmune disease — discoveries that now point to new treatments in cancer and autoimmunity.
Dr. Wei Wei has developed a promising new companion diagnostic tool called MetaboCore to help physicians quickly select the most effective systemic therapy for each cancer patient.
Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.
ISB President Dr. Jim Heath talks with Nobel laureate and Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center Dr. Jim Allison and Apricity Health CEO Dr. Lynda Chin. Drs. Heath, Allison and Chin discuss disparities in cancer care and ways to bring state-of-the-art care from big cities and major academic centers to rural and underserved areas.
The NCI awarded ISB a 5-year, $13 million grant to lead a comprehensive cancer center and study sequential combinations of targeted inhibitors and immunotherapies. The program is designed to determine if the treatments yield greater patient benefit when administered in sequence rather than as monotherapies or as simultaneously administered combinations.
A recently developed method by the Wei Lab at Institute for Systems Biology (ISB) and University of California, Riverside provides new insights into cancer biology by allowing researchers to show how fatty acids are absorbed by single cells. This work was published in the Journal of the American Chemical Society.
To improve the efficacy of neoadjuvant immune checkpoint blockade against glioblastoma, researchers are looking for vulnerabilities in surgically removed tissues – a difficulty due to the vast differences within the tumor and between patients. To address this, ISB researchers and their collaborators developed a new way to study tumors.